Research on Tamoxifen resistance from SABCS

Options
jojo9999
jojo9999 Member Posts: 202
edited October 2016 in Clinical Trials, Research News, Podcasts, and Study Results


http://www.onclive.com/conference-coverage/sabcs-2...

· Share on FacebookShare on Twitter

Comments

  • JohnSmith
    JohnSmith Member Posts: 651
    edited October 2016

    Yes. Thanks! This was added to the "San Antonio Breast Cancer Symposium 2015. Dec.8-12" thread here, and probably warrants its own post.

    To recap...

    Resistance of ER-positive Breast Cancer to Tamoxifen Therapy May be Driven by APOBEC3B
    Responses to Tamoxifen (Tam) were significantly prolonged by reducing levels of the enzyme APOBEC3B in preclinical models of ER+ breast cancer and significantly shortened by increasing levels of APOBEC3B, suggesting that APOBEC3B drives resistance to Tam.
    "Several recent studies have linked elevated levels of the enzyme APOBEC3B in ER+ with poor patient outcomes, but whether APOBEC3B actually drives the poor outcomes has not been determined," said Reuben Harris, PhD, professor in the Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota, Twin Cities.
    "We know that APOBEC3B is not required for human life because a large proportion of people in Southeast Asia do not have APOBEC3B as a result of a natural genetic variation," Harris continued. "This, combined with the fact that it is an enzyme, makes APOBEC3B an attractive target for a therapeutic that could stop the development of resistance mutations and substantially extend the length of response to Tam."
    * Note: While interesting, this is lab research. Clinical trials would be needed to validate. Does a APOBEC3B inhibitor even exist?

    For a simpler explanation of this APOBEC3B enzyme at its potential connection to Tam resistance,
    watch this 2 minute video by Dr. Reuben Harris.
    · Share on FacebookShare on Twitter
  • Heidihill
    Heidihill Member Posts: 5,476
    edited December 2015

    Wonder where they got the info on Southeast Asians? Hoping it's true and I'm one of those lucky ones now that I'm on Tamoxifen.

    · Share on FacebookShare on Twitter
  • JohnSmith
    JohnSmith Member Posts: 651
    edited October 2016

    More news about "APOBEC3B" and Tamoxifen (Tam) resistance.

    Using clinical data and mouse models UMN scientists confirmed that the protein APOBEC3B (or simply "A3B") is responsible for reduced response to Tam therapy in breast cancer.

    Lay version of news: http://twin-cities.umn.edu/news-events/culprit-found-breast-cancer-resistance-tamoxifen

    Science version: http://advances.sciencemag.org/content/2/10/e1601737


    · Share on FacebookShare on Twitter

Categories